Mar 11, 2019 / 03:20PM GMT
Yaron Benjamin Werber - Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
Okay. Well, good afternoon, everybody or good late morning, and thank you so much for joining us for the 39th annual health care conference at Cowen. And it's a great pleasure to introduce Bob Landry, CFO; and Jay Markowitz, SVP of Portfolio Management for Regeneron.
Questions and Answers:
Yaron Benjamin Werber - Cowen and Company, LLC, Research Division - MD & Senior Biotechnology AnalystSo we have, I think, a fairly aggressive agenda. So we want to talk about financial view for the company over time and the collaboration with Sanofi, and then, obviously, drilling into the pipeline as well. But I think, first, I think it's worthwhile taking a step back and talking about Regeneron broadly as a company and culturally and capability-wise and expertise-wise what makes Regeneron different. And the company was ranked #1 yet again in the biopharma survey. You're the #1 employer. And I know you're both newer to the Regeneron story that's been ongoing for
Trustpilot
